| Sign In to gain access to subscriptions and/or personal tools. |
Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosusAlexion Pharmaceuticals Inc., Chesire, CT, USA
Alexion Pharmaceuticals Inc., Chesire, CT, USA
Alexion Pharmaceuticals Inc., Chesire, CT, USA, mccroskerye{at}alxn.com The importance of the complement system in the pathophysiology of systemic lupus erythematosus (SLE) is clear although individual complement components play very different roles in the disease process. Early complement proteins are critical in the clearance of immune complexes and apoptotic bodies, and their absencepredisposesindividualsto SLE. Conversely, activationof terminalcomplement is associated with exacerbations of disease and damage to tissues and organs, particularly in lupus nephritis. Monoclonal antibodies that specifically inhibit terminal complement activation while preserving the critical functions of the early complement cascade have now been developed. These antibodies target the C5 complement protein, blocking its cleavage and the subsequent generation of potent proinflammatory molecules. Anti-C5 therapeutics have recently been investigated in an animal model of SLE and in a Phase I single dose study in humans. The results of these studiesand the multiple roles of complement in SLE are discussed.
Key Words: anti-C5 antibody • C5a • C5b-9 • complement • systemic lupus erythematosus
Lupus, Vol. 13, No. 5,
328-334 (2004) This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
